Glucozid (Gliclazide) is a hypoglycemic agent of the sulfonylurea group. The hypoglycemic action of Gliclazide is related to an improvement in insulin secretion from the functioning beta cells of the pancreas.


Gliclazide is a second-generation oral hypoglycemic sulfonylurea, which stimulates the release of insulin from pancreatic beta cells by facilitating Ca++ transport across the beta-cell membrane and decreases hepatic glucose output.


    Glucozid Tablet: Each Glucozid tablet contains Gliclazide BP 80 mg.


    Glucozid (Gliclazide) is indicated for control of blood glucose in patients with non-insulin dependent diabetes mellitus (Type-II, maturity onset diabetes mellitus) whose hyperglycemia cannot be controlled by diet alone.

Dosage & Administration

    Initially, 40-80 mg daily adjusted according to response, up to 160 mg as a single dose with breakfast; higher doses divided; Max. 320 mg daily.


    Hypersensitivity to sulfonylurea, diabetes complicated by ketoacidosis with coma, as a sole therapy of insulin-dependent (Type-1) diabetes mellitus, diabetes when complicated by pregnancy & breast-feeding.

Warning & Precautions

    Care should be exercised in patients with hepatic and/or renal impairment. In long term clinical trials patients with renal insufficiency have been treated satisfactory using Gliclazide at reduced doses.

Side effects

    Hypoglycemia may occur in concurrent conditions such as hepatic & renal diseases, alcohol intoxication and adrenal & pituitary insufficiency.

    Gastro-intestinal disturbances such as vomiting, diarrhoea & cinstipation.
    Allergic skin reactions including rash, pruritus and erythema, urticarias have been reported. These may be transient and may disappear despite continued use of the drug.

Drug interaction

Use in special groups

    In pregnancy & Lactation: Gliclazide should not be used.


    Glucozid Tablet: Each box contains 60's tablets in blister pack.